Circulating Neoplastic Cells

USE OF PARSORTIX SYSTEM IN PRE-CLINICAL MODEL UNLOCKS OPPORTUNITIES FOR DRUG DISCOVERY Harvested CTCs reveal gene expression pro with development and progression of brain metastasis in melanoma Researchers suggest such profiling could prove to be "pivotal" to prescribing more targeted treatments in this setting GUILDFORD, SURREY / ACCESSWIRE / December 11, 2023 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology, is delighted to announce the publication of breakthrough work by researchers at the University of New Mexico, US, into the role of CTC gene expression in the progression of melanoma brain metastasis. The researchers used the Parsortix system to harvest CTCs for analysis and concluded that "… gene expression in CTCs could be pivotal to prescribing more targeted treatment based on the needs of the patient." In this study, pre-clinical mouse models of melanoma brain metastasis were split into four treatment groups and two cancer drugs were tested individually and together vs. placebo. Blood samples were analysed using the Parsortix system to harvest CTCs. The authors found that using the two drugs together was the most effective therapeutic regime, reducing tumour burden, metastasis and CTC count. This research provides further evidence of the capability of the Parsortix system to be used for the harvesting of CTCs for analysis in pre-clinical mouse models. The global market for preclinical clinical research organisations exceeded a valuation of US$ 5 billion in 2022 and is expected to achieve a 7.5% CAGR over the next 10 years owing to increasing R&D expenditure on early-stage development combined with the growing number of drugs in preclinical development. ANGLE Chief Executive Officer, Andrew Newland, commented: "The use of CTC biomarkers in clinical trials is a rapidly growing field enabling longitudinal monitoring of transcriptomic and proteomic changes. ANGLE can provide pharma customers with a complete range of services to support preclinical and clinical drug development. This includes standardised and validated protocols for analysing CTCs including the established techniques of IF, dPCR and NGS, and the capability to deliver bespoke assays to identify drug targets and ascertain therapeutic efficacy." This peer-reviewed journal article is published in the journal of Cancers and available at . ANGLE plc +44 (0) 1483 343434 Andrew Newland, Chief Executive Ian Griffiths, Finance Director Berenberg (NOMAD and Broker) Toby Flaux, Ciaran Walsh, Milo Bonser +44 (0) 20 3207 7800 FTI Consulting Simon Conway, Ciara Martin Matthew Ventimiglia (US) +44 (0) 203 727 1000 +1 (212) 850 5624 For Frequently Used Terms, please see the Company's website on Notes for editors About ANGLE plc ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) diagnostic solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumour cell (CTC) harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis. ANGLE's commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix® system and associated consumables. The clinical services business is offered through ANGLE's GCP-compliant laboratories in the UK and the United States. Services include custom made assay development and clinical trial testing for pharma. Over 90 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit . SOURCE: ANGLE plc View the original press release on accesswire.com

HANGZHOU, China, Aug. 9, 2023 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced positive topline data from a Phase II clinical trial of LNK01001 for the treatment of atopic dermatitis. The study was a randomized, double-blind, placebo-controlled, multicenter Phase II trial conducted in adult patients (aged 18-75) with moderate-to-severe atopic dermatitis (AD) who had previously received inadequate response to topical treatment for AD or had previously received other systemic treatment for AD. The study was led by Professor Jianzhong Zhang, Director of the Dermatology Department at Peking University People's Hospital. A total of 150 patients were enrolled in the trial. The patients were randomly divided into three trial groups at a ratio of 1:1:1, namely LNK01001 high-dose, low-dose, and placebo groups. The primary efficacy endpoint of the study was the percentage change from baseline in the eczema area and severity index (EASI) score at Week 12. Preliminary data showed that after 12 weeks of treatment, patients in both the high and low dose groups showed significant improvement, with a statistically significant difference in the percentage change from baseline in EASI score compared to the placebo group, achieving the primary endpoint. Additionally, the proportion of responders achieving EASI-75 (≥75% improvement from baseline in EASI score) and Investigator's Global Assessment (IGA) response[1] were significantly higher in both high and low dose groups of LNK01001 compared to the placebo group. Improvement of pruritus is an important indicator of quality of life for patients with atopic dermatitis, and the results of the trial showed that LNK01001 had a rapid onset of improvement in pruritus, with both the high and low dose groups of LNK01001 showing significantly better improvement in pruritus indices than the placebo group at 24 hours after dosing. In terms of safety, both high and low dose groups of LNK01001 demonstrated good overall tolerability, with comparable rates of CTC grade 2+ treatment-emergent adverse events (TEAE) and serious adverse events (SAE) compared to the placebo group. No major adverse cardiovascular events (MACE), venous thromboembolism (VTE), malignancies, or severe infections were reported. Professor Jianzhong Zhang, the principal investigator of this study, the 13th Director in the Dermatology Division of the Chinese Medical Association and Director of the Dermatology Department at Peking University People's Hospital, said, "Atopic dermatitis is a disease characterized by chronic, recurrent pruritus and polymorphic inflammatory skin lesions. Controlling itch and clearing skin lesions are the most urgent treatment needs for AD patients. The results of this study suggest that LNK01001 has the potential to provide clinical benefits to adult patients with moderate to severe AD. We will continue to conduct further research and look forward to validating the efficacy and safety of LNK01001 in Phase III clinical trials to benefit more patients." "With social development and lifestyle changes, the number of atopic dermatitis patients is increasing, with a global population of 390 million. We are pleased to see that LNK01001 has shown positive results in the treatment of atopic dermatitis", said Dr. Henry Wu, Chief Development Officer of Lynk Pharmaceuticals, "We are preparing to submit an application for the End of Phase II (EOP2)/Pre-Phase III meeting to advance the clinical development of this compound and strive to benefit more patients as soon as possible." Note: [1]: IGA response is defined as achieving an IGA score of 0 or 1 (complete or near-complete clearance of skin lesions) and an improvement of ≥2 points from baseline. About Lynk Pharmaceuticals: Lynk Pharmaceuticals, a clinical stage company, was founded in 2018 by senior drug R&D experts and executives from Pfizer, Merck, and Johnson & Johnson. Lynk Pharmaceuticals is dedicated to the discovery and development of innovative drugs for the treatment of cancer, as well as immune and inflammatory diseases. Driven by a higher goal, Lynk Pharmaceuticals aims to be a market leader to address unmet medical demands by the development of innovative therapies. To date, Lynk Pharmaceuticals has independently developed several innovative new drugs and successfully completed a number of clinical studies. For more information about Lynk Pharmaceuticals, please visit: . SOURCE Lynk Pharmaceuticals Co., Ltd.

DUBLIN, Feb. 10, 2023 /PRNewswire/ -- The "Circulating Tumor Cell (CTC) Diagnostics: Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global market for Circulating Tumor Cell (CTC) Diagnostics estimated at US$9.1 Billion in the year 2022, is projected to reach a revised size of US$21.3 Billion by 2030, growing at a CAGR of 11.2% over the analysis period 2022-2030. Detection & Enrichment, one of the segments analyzed in the report, is projected to record a 10.8% CAGR and reach US$13.8 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Analysis segment is readjusted to a revised 12.8% CAGR for the next 8-year period. The U.S. Market is Estimated at $2.7 Billion, While China is Forecast to Grow at 10.3% CAGR The Circulating Tumor Cell (CTC) Diagnostics market in the U.S. is estimated at US$2.7 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$3.6 Billion by the year 2030 trailing a CAGR of 10.3% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 10.2% and 9.5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 7.9% CAGR. Select Competitors (Total 48 Featured) - ApoCell, Inc. Biocep Ltd. Biocept, Inc. Biofluidica Microtechnologies LLC Celltraffix Inc. Clearbridge Biomedics Creatv Microtech, Inc. Cynvenio Biosystems, Inc. Fluxion Biosciences, Inc. Ikonisys, Inc. IVDiagnostics, Inc. Janssen Diagnostics LLC QIAGEN Hannover GmbH Rarecells Sas Screencell Stemcell Technologies, Inc. What`s New for 2023? Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession. Global competitiveness and key competitor percentage market shares Market presence across multiple geographies - Strong/Active/Niche/Trivial Online interactive peer-to-peer collaborative bespoke updates Access to digital archives and Research Platform Complimentary updates for one year Key Topics Covered: I. METHODOLOGY II. EXECUTIVE SUMMARY 1. MARKET OVERVIEW Influencer Market Insights World Market Trajectories Market Outlook Recent Market Activity Clinical Relevance of CTCs CTC Detection - Real-Time 'Liquid Biopsy' Scores Over Surgical Biopsy Major Challenges in CTC Diagnostics Need for CTC Enrichment and Popular Methods CTC Enrichment Techniques Select Available CTC Detection Technologies Select CTC Isolation Systems - A Brief Comparison CTC Identification - Various Approaches CTC Identification Approaches List of mRNA Markers for RT-PCR-based Detection of CTCs by Tumor Type CellSearch SystemT - The First FDA Approved Automated Enrichment/Isolation Technique Rising Incidence of Cancer - An Opportunity Indicator Cancer Prone Sites based on Age Circulating Tumor Cell (CTC) Diagnostics - Global Key Competitors Percentage Market Share in 2022 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E) Impact of Covid-19 and a Looming Global Recession 2. FOCUS ON SELECT PLAYERS 3. MARKET TRENDS & DRIVERS Liquid Biopsy - the New Buzzword in Healthcare Select Companies Active in Cancer Liquid Biopsy CTCs for Personalized Cancer Treatment Microfluidic Chip-based Technologies - A Promising Avenue for Cancer Diagnosis CTC Microdevices Hog the Limelight Increasing Research Reveal Further Complexities to CTC Composition and Behavior EpCAM Glycoprotein - Insufficient for CTC Detection New Isolation Techniques Show Promise in Detecting EpCAM-Negative CTCs Physical Property-based Enrichment Technologies Lose Fizz Evidence in Favor CTC Heterogeneity Gains Strength CTC Clusters Raise Research Interest Detection of EMTs Gains Precedence in the Backdrop of Recent Research Findings Limitations of CTC Technology for Point-of-Care Testing CTC Technologies Offer an Edge over Imaging Tests for Breast Cancer Prognosis Limited Biomarkers Utilized In CTC Diagnostics - A Threat to Market Growth? Select Research Findings in Recent Years Microfluidic Device with Micro-Hall Sensors Detect CTCs with Higher Sensitivity and Specificity NBiomics Makes its Contribution to CTC Diagnosis Researchers at University of Michigan Develop Revolutionary Capture CTCs Method Dean Flow Fractionation to Overcome Limitations Associated with Conventional Biomarker Analysis Gold Nanoparticles Help in the Detection of CTCs 4. GLOBAL MARKET PERSPECTIVE III. MARKET ANALYSIS IV. COMPETITION For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets